Salarius Pharmaceuticals, Inc. (SLRX)
$1.74
Rating:
Recommendation:
-
| Symbol | SLRX |
|---|---|
| Price | $1.74 |
| Beta | 1.123 |
| Volume Avg. | 0.10M |
| Market Cap | 5.833M |
| Shares () | - |
| 52 Week Range | 1.07-7.2 |
| 1y Target Est | - |
| DCF Unlevered | SLRX DCF -> | |
|---|---|---|
| DCF Levered | SLRX LDCF -> | |
| ROE | -185.92% | Strong Sell |
| ROA | -289.65% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 41.08% | Neutral |
| P/E | -0.11 | Neutral |
| P/B | 0.36 | Neutral |
Latest SLRX news
About
Download (Excel)Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.